Vimarsana
Biggest News Aggregation in the World

Page 24 - Priya Singhal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Priya Singhal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Priya Singhal Today - Breaking & Trending Today

Himension Capital Singapore PTE. LTD. Purchases New Shares in Biogen Inc. (NASDAQ:BIIB) - Vimarsana News

Himension Capital Singapore PTE. LTD. Purchases New Shares in Biogen Inc. (NASDAQ:BIIB)

Himension Capital Singapore PTE. LTD. purchased a new position in Biogen Inc. (NASDAQ:BIIB – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 998 shares of the biotechnology company’s stock, valued at approximately $256,000. Several other large investors […]

Biogen: approval for Friedreich's ataxia in the EU -February 13, 2024 at 01:12 am EST - Vimarsana News

Biogen: approval for Friedreich's ataxia in the EU -February 13, 2024 at 01:12 am EST

Biogen announces that the European Commission has granted marketing authorization for its Skyclarys for the treatment of Friedreich's ataxia in adults and adolescents over the age of 16.Skyclarys is...

Analysts Set Biogen Inc. (NASDAQ:BIIB) PT at $318.17 - Vimarsana News

Analysts Set Biogen Inc. (NASDAQ:BIIB) PT at $318.17

Biogen Inc. (NASDAQ:BIIB – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the twenty-six brokerages that are currently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. The average 12 month price target […]

Source: wkrb13.com
Biogen's (BIIB) "Buy" Rating Reiterated at Needham & Company LLC - Vimarsana News

Biogen's (BIIB) "Buy" Rating Reiterated at Needham & Company LLC

Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $305.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s price target would suggest a potential […]

First treatment for Friedreich's ataxia in Europe granted approval - Vimarsana News

First treatment for Friedreich's ataxia in Europe granted approval

Biogen Inc. has taken a step closer to bringing its ‘groundbreaking treatment’ to patients with a rare, genetic, life-shortening, debilitating, and neurodegenerative disorder.